Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Rockwell Medical, Inc.
Type
Public
Traded as NASDAQ: RMTI
Industry Pharmaceutical Industry
Founded 1996
Headquarters United States, Wixom, Michigan
Key people

Robert L. Chioini, Founder, Chairman and CEO Thomas E. Klema, Vice President, CFO, Treasurer and Secretary Ajay Gupta, M.D., Chief Scientific Officer

Raymond D. Pratt, M.D, Chief Medical Officer
Website www.rockwellmed.com

Robert L. Chioini, Founder, Chairman and CEO Thomas E. Klema, Vice President, CFO, Treasurer and Secretary Ajay Gupta, M.D., Chief Scientific Officer

Rockwell Medical Inc. is a publicly traded (NASDAQ: RMTI) biopharmaceutical company founded in 1996 in Michigan. Rockwell focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).

This company performed top during 2013, among biopharmaceutical companies in the US and has two largest dialysis centers in the US, DaVita (DVA) and Fresenius (FMS), as the buyer of its products.

Triferic: Triferic was approved by United States Food and Drug Administration (FDA) in January 2015. Triferic is the only FDA-approved therapy indicated to replace iron and maintain hemoglobin in adult hemodialysis patients with chronic kidney disease. Triferic replaces the iron lost during hemodialysis treatments. Triferic delivers iron directly to transferrin which transported it to the bone marrow to make hemoglobin. Rockwell is actively marketing and commercializing Triferic in the U.S. hemodialysis market.

Calcitriol: Calcitriol (active vitamin D) generic is FDA approved for treating secondary hyperparathyroidism or hypocalcemia in hemodialysis patients.

Hemodialysis Concentrates: Rockwell is an established manufacturer of hemodialysis concentrates/dialysates for dialysis providers and distributors in the U.S. and globally. Hemodialysis concentrates remove toxins and replace critical nutrients in the dialysis patient’s bloodstream during hemodialysis. Rockwell has three U.S. manufacturing and distribution facilities.

One of the main treatment that the company develops is for iron supplementation, a key element in the formation of new red blood cells. The product is called soluble ferric pyrophosphate (SFP), and its therapy was licensed in 2011 for the delivery of iron supplementation for patients who suffer from anemic dialysis, since the process accounts for treatment in around 90 percent of anemia patients. The clinical experiment for this treatment is under Phase III during 2011.

In February 2014, the Company completed its large-scale, long-term safety study for iron maintenance drug Triferic.

In December 2011, Rockwell Medical Inc. acquired an abbreviated new drug application (ANDA), which is used for calcitriol, an intravenous Vitamin D analogue, in a gene-related version.

Investment goal date:
Dividends reinvested
Rockwell Medical, Inc. RMTI report Q3 2017
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2018
2018-05-08
--
--
Q4 2017
2018-03-13
--
--
Q4 2017
2018-03-05
--
--
Q3 2017
2017-11-08
-0.1000
0.0000
Q3 2017
2017-11-06
--
--
Q2 2017
2017-08-09
-0.1400
-0.1400
Q1 2017
2017-05-09
-0.0900
-0.0900
Q4 2016
2017-03-15
-0.1000
-0.1000
Q3 2016
2016-11-07
-0.0900
-0.0900
Q2 2016
2016-08-08
-0.1100
-0.1100
Q1 2016
2016-05-10
-0.0900
-0.1000
Q4 2015
2016-02-29
-0.1200
-0.1200
Q3 2015
2015-11-09
-0.0500
-0.0500
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
Bank of New York Mellon Corp
234246
BlackRock Fund Advisors
1539718
BlackRock Inc.
3027624
BlackRock Institutional Trust Company, N.A.
1250710
BlackRock Investment Management, LLC
190543
D. E. Shaw & Co., Inc.
244208
GEODE CAPITAL MANAGEMENT, LLC
371700
Longwood Capital Partners LLC
140000
NORTHERN TRUST CORP
589563
PERKINS CAPITAL MANAGEMENT INC
485433
PERRITT CAPITAL MANAGEMENT INC
182367
STATE STREET CORP
841048
STIFEL FINANCIAL CORP
176038
TIAA CREF INVESTMENT MANAGEMENT LLC
130730
Vanguard Group, Inc
1990057
Major Shareholders
Name Relationship
Total Shares
Holding stocks
RAVICH MARK H
0.0200% (10000)
RMTI / TIS /
HAGELSTEIN DAVID A
3.3300% (1360700)
RMTI /
CHIOINI ROBERT L
6.2200% (2544983)
RMTI /
KLEMA THOMAS E
1.6400% (670167)
RMTI /
BOYD RONALD D
0.1000% (42300)
RMTI /
HOLT KENNETH L
0.0300% (12630)
RMTI /
Bagley Patrick J
0.2800% (115550)
RMTI /
Smith Robin L
0.0200% (9800)
NBS / RMTI / SGNL /
Gupta Ajay
1.2000% (490949)
RMTI /
Pratt Raymond Dennis
0.7800% (317970)
RMTI /
% ()